Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2013

01-07-2013 | Original Paper

Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor

Authors: Sang-Woo Lim, Hye-Ran Kim, Hwan-Young Kim, Jung-Wook Huh, Young-Jin Kim, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang, Hyeong-Rok Kim, Myung-Geun Shin

Published in: Cellular Oncology | Issue 4/2013

Login to get access

Abstract

Background

Currently, conflicting information exists regarding Her-2 over-expression and its clinicopathological implications in colorectal cancer (CRC). This study was undertaken to determine Her-2 over-expression in both serum and tumor tissue of CRC patients, and to assess its clinicopathological and targeted therapeutic implications.

Methods

Ninety five CRC patients and sixty healthy controls were prospectively enrolled. Her-2 expression status in serum and CRC tissue were examined by chemiluminescent immunoassay and immunohistochemical staining, respectively. The results were confirmed using fluorescent in situ hybridization. Clinicopathological parameters were analyzed according to Her-2 expression status.

Results

Serum Her-2 levels were found to be increased in CRC patients as compared to those of healthy controls. However, serum Her-2 levels were not found to be significantly associated with prognostic parameters. Her-2 expression analysis of CRC tissues revealed Her-2 over-expression in 23 patients (25%), i.e., 13 patients (14%) showed moderate over-expression and 10 patients (11%) showed strong over-expression. The overall survival of patients negative for Her-2 expression was significantly better than that of patients positive for Her-2 expression (P = 0.018). The disease-free survival of patients with Her-2 over-expression was significantly shorter than that of patients with no Her-2 expression (P = 0.021).

Conclusions

Her-2 over-expression in CRC tissue, but not in serum, acts as a significant independent worse prognostic factor. Assessment of Her-2 expression status may be valuable for the targeted therapeutic management of CRC.
Literature
1.
Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)PubMedCrossRef
2.
E. Half, R. Broaddus, K.D. Danenberg, P.V. Danenberg, G.D. Ayers, F.A. Sinicrope, HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 108, 540–548 (2004)PubMedCrossRef
3.
4.
S. Riethdorf, V. Muller, L. Zhang, T. Rau, S. Loibl, M. Komor et al., Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 16, 2634–2645 (2010)CrossRef
5.
D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783–792 (2001)PubMedCrossRef
6.
C. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher et al., First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 37(Suppl 1), S25–S29 (2001)PubMedCrossRef
7.
K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos et al., Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Trans. Med. 3(99ra86) (2011)
8.
A.H. Marx, E.C. Burandt, M. Choschzick, R. Simon, E. Yekebas, J.T. Kaifi et al., Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 41, 1577–1585 (2010)PubMedCrossRef
9.
B. Schuell, T. Gruenberger, W. Scheithauer, C. Zielinski, F. Wrba, HER 2/neu protein expression in colorectal cancer. BMC Cancer. 6, 123 (2006)PubMedCrossRef
10.
J.S. Ross, B.J. McKenna, The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 19, 554–568 (2001)PubMedCrossRef
11.
T. Osako, M. Miyahara, S. Uchino, M. Inomata, S. Kitano, M. Kobayashi, Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 55, 548–555 (1998)PubMedCrossRef
12.
S. Kapitanovic, S. Radosevic, M. Kapitanovic, S. Andelinovic, Z. Ferencic, M. Tavassoli et al., The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112, 1103–1113 (1997)PubMedCrossRef
13.
K. Al-Kuraya, H. Novotny, P. Bavi, A.K. Siraj, S. Uddin, A. Ezzat et al., HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60, 768–772 (2007)PubMedCrossRef
14.
J.A. McKay, J.F. Loane, V.G. Ross, M.M. Ameyaw, G.I. Murray, J. Cassidy et al., c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 86(568–73) (2002)
15.
Q. Li, D. Wang, J. Li, P. Chen, Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 11, 277 (2011)PubMedCrossRef
16.
S.Y. Kong, J.H. Kang, Y. Kwon, H.S. Kang, K.W. Chung, S.H. Kang et al., Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol 59, 373–376 (2006)PubMedCrossRef
17.
V. Ludovini, S. Gori, M. Colozza, L. Pistola, E. Rulli, I. Floriani et al., Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 19, 883–890 (2008)PubMedCrossRef
18.
S.Y. Yan, Y. Hu, J.G. Fan, G.Q. Tao, Y.M. Lu, X. Cai et al., Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 17, 1501–1506 (2011)PubMedCrossRef
19.
D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989)PubMedCrossRef
20.
M. Herreros-Villanueva, M. Rodrigo, M. Claver, P. Muniz, E. Lastra, C. Garcia-Giron et al., KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 38, 1315–1320 (2011)PubMedCrossRef
21.
D.R. Nathanson, A.T. Culliford, J. Shia, B. Chen, M. D’Alessio, Z.S. Zeng, HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105, 796–802 (2003)PubMedCrossRef
22.
R.K. Ramanathan, J.J. Hwang, W.C. Zamboni, F.A. Sinicrope, H. Safran, M.K. Wong et al., Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22, 858–865 (2004)PubMedCrossRef
23.
S.Y. Kong, B.H. Nam, K.S. Lee, Y. Kwon, E.S. Lee, M.W. Seong et al., Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 52, 1510–1515 (2006)PubMedCrossRef
24.
A. Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle et al., Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20, 1467–1472 (2002)PubMedCrossRef
25.
H.J. Cho, S.Y. Lee, J.W. Kim, Evaluation for the clinical usefulness of serum HER-2/neu oncoprotein in patients with breast cancer. Korean J Lab Med. 24, 215–222 (2004)
26.
S.H. Kang, J. Cho, J.S. Ha, S.Y. Kwon, Evaluation of serum HER-2/neu extracelluar domain in breast cancer patients: correlation with tissue HER-2/neu status and clinicopathological factors. J Korean Surg Soc. 78, 271–276 (2010)CrossRef
27.
M. Quaranta, A. Daniele, M. Coviello, A. Savonarola, I. Abbate, M.T. Venneri et al., c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori 92(311–317) (2006)
Metadata
Title
Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor
Authors
Sang-Woo Lim
Hye-Ran Kim
Hwan-Young Kim
Jung-Wook Huh
Young-Jin Kim
Jong-Hee Shin
Soon-Pal Suh
Dong-Wook Ryang
Hyeong-Rok Kim
Myung-Geun Shin
Publication date
01-07-2013
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2013
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-013-0136-6

Other articles of this Issue 4/2013

Cellular Oncology 4/2013 Go to the issue

Original Paper

Visualising and quantifying angiogenesis in metastatic colorectal cancer

Original Paper

Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas

Review

Lung cancer stem cells: a biological and clinical perspective

Original Paper

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

Original Paper

In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation

OriginalPaper

Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits